Practice
Coagulopathy associated with COVID-19
Stephanie G. Lee, Michael Fralick and Michelle Sholzberg
CMAJ May 25, 2020 192 (21) E583; DOI: https://doi.org/10.1503/cmaj.200685
Stephanie G. Lee
St. Michael’s Hospital (Lee) and Department of Medicine, University of Toronto; Sinai Health System and Department of Medicine (Fralick), University of Toronto; St. Michael’s Hospital and Departments of Medicine, and Laboratory Medicine and Pathobiology (Sholzberg), Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ont.
MD MScMichael Fralick
St. Michael’s Hospital (Lee) and Department of Medicine, University of Toronto; Sinai Health System and Department of Medicine (Fralick), University of Toronto; St. Michael’s Hospital and Departments of Medicine, and Laboratory Medicine and Pathobiology (Sholzberg), Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ont.
MD PhDMichelle Sholzberg
St. Michael’s Hospital (Lee) and Department of Medicine, University of Toronto; Sinai Health System and Department of Medicine (Fralick), University of Toronto; St. Michael’s Hospital and Departments of Medicine, and Laboratory Medicine and Pathobiology (Sholzberg), Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ont.
MDCM MScData supplements
Français
Related Articles
- Lee, S. G., Fralick, M., & Sholzberg, M. (2020). Coagulopathie associée à la COVID-19. CMAJ, 192(45), E1424. Accessed March 28, 2024. https://doi.org/10.1503/cmaj.200685-f.
In this issue
Article tools
Respond to this article
Coagulopathy associated with COVID-19
Stephanie G. Lee, Michael Fralick, Michelle Sholzberg
CMAJ May 2020, 192 (21) E583; DOI: 10.1503/cmaj.200685
Jump to section
- Article
- About 20%–55% of patients admitted to hospital for coronavirus disease 2019 (COVID-19) have laboratory evidence of coagulopathy
- Elevated d-dimer concentration is associated with poor clinical outcomes
- COVID-19-associated coagulopathy appears to be prothrombotic
- In the absence of a contraindication, patients admitted to hospital should receive venous thromboembolism prophylaxis as per standard of care
- Transfusion of blood products should be avoided in patients who do not have active, major bleeding
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- Leveraging genetic data to elucidate the relationship between Covid-19 and ischemic stroke
- Axillary artery thrombosis resulting in upper limb amputation as a COVID-19 sequela
- Prevoir et gerer la coagulopathie et les manifestations thrombotiques de la COVID-19 severe
- Identification of potential coagulation pathway abnormalities in SARS-Cov-2 infection; insights from bioinformatics analysis
- Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19